Depends on what you mean by long term. Anybody who bought in 2024 is doing splendidly well but people who bought years ago probably not so. That is why I never buy biotech on or near IPO price because multiple CRs are almost inevitable.
The only company where I might consider an exception is RNV because they already have an FDA approved product and another product in development that may rival or surpass OCC. Not ramping, since I don't own shares in RNV or OCC, just simply pointing out the rare exception.
ATH Price at posting:
1.2¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)